SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as escalating geopolitical tensions involving the US, Israel, and Iran have sent crude oil prices soaring, sparking intense community debate between those predicting a market crash and others anticipating a swift rebound, all while global economic impacts remain a key concern.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending due to escalating Middle East conflict, including attacks on oil facilities and production cuts by key regional producers, which has led to concerns over global supply as the Strait of Hormuz remains restricted. Community sentiment is sharply divided, with some anticipating significant further rallies while others expect a sharp pullback given perceived overbought conditions and potential government interventions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp is trending as escalating Middle East tensions, including reports of oil facility attacks and supply route disruptions, drive crude prices sharply higher, with the community anticipating a significant short squeeze and drawing comparisons to past rallies for the low-float energy stock.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors anticipate its upcoming earnings report, with community sentiment sharply divided between those highlighting its deeply oversold status, strong AI advancements, and a recent Goldman Sachs 'Conviction Buy' upgrade. Conversely, significant geopolitical and regulatory concerns continue to weigh on the broader Chinese tech sector, driving heated discussions.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

With crude oil prices skyrocketing amid escalating geopolitical tensions and supply concerns, $SCO is drawing significant attention from traders aggressively betting on a sharp market reversal. The community is actively discussing entry points and drawing parallels to past commodity downturns, anticipating oil's eventual return to lower levels.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending as escalating tensions in the Middle East, particularly concerning Iran and the Strait of Hormuz, drive significant speculation of crude oil supply disruptions. The community is sharply divided, with many anticipating substantial price hikes for the leveraged ETF, while others caution about fundamental oversupply or the instrument's historical tracking.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as escalating Middle East tensions, marked by a new Iranian Supreme Leader and attacks on oil infrastructure, are driving crude prices sharply higher and causing global markets to plunge. Community discussion is split between anticipating a significant crash and identifying "buy the dip" opportunities, reflecting broad concern over the conflict's economic fallout.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a mixed earnings report that saw it beat Q4 estimates and announce a $30 billion share repurchase program along with a dividend increase, though conservative future guidance has sparked debate. The community is divided between those optimistic about its digital growth, record revenue, and defensive appeal, and others concerned about its high valuation amid a cautious outlook.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply upward following reports of a strategic partnership with Novo Nordisk to sell obesity drugs, effectively ending their legal dispute. The community is highly anticipating a significant short squeeze, given the substantial short interest, and is collectively pushing to maximize gains.

United States Commodity Funds LLC - United States Brent Crude Oil Fund

BNO is trending as escalating geopolitical tensions in the Middle East, fueled by reports of attacks and concerns over supply disruptions, are driving a sharp rally in Brent crude prices. The community is buzzing with bullish sentiment for oil, while also debating the broader economic impact and potential for further price surges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Shares of Phio Pharmaceuticals Corp. (PHIO) traded 63% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://phiopharma.com/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-advance-intasyl-ph-762-skin-cancer-study-to-fourth-dose-escalation-cohort/">announced</a> that a Safety Monitoring Committee (SMC) recommended escalating the dose in the clinical trial for its lead product candidate, PH-762.The dose-escalating clinical trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in certain skin cancers. The trial assesses tumor response and determines the recommended dose for further study of the product candidate.PH-762 is an Intasyl compound that silences the PD-1 gene implicated in various forms of skin cancer.CEO Robert Bitterman said the company is optimistic the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.The company said that two of four patients diagnosed with cutaneous squamous cell carcinoma and enrolled in the second cohort of the trial had 100% tumor clearance upon excision.While one had a 90% tumor clearance, the fourth patient maintained stable disease, the company said.Three patients were enrolled in the third cohort of the trials. The injections were well tolerated with no serious adverse events, the company said.On Stocktwits, retail sentiment around Phio Pharmaceuticals rose from ‘bearish’ to ‘extremely bullish’ while message volume jumped from ‘high’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:1298/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_1_47_54_PM_png_f2666fba4f.webp" alt="PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="1298" height="298"><figcaption>PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PHIO">PHIO shares</a> rose as high as $2.73 on Wednesday before paring gains to around $1.50.The stock fell by over 13% this year and by over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacbio-plans-to-reduce-spending-over-nih-funding-uncertainty-tariffs/chfnXrfRbBd">PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer. 

Equity

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Shares of Phio Pharmaceuticals Corp. (PHIO) nearly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/phio-stock-rockets-on-cancer-trial-data/chGNgCORNj">quadrupled</a> on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to enhance the immune system's ability to target tumors.However, the nanocap stock reversed course on Tuesday, plunging over 50% following news of a registered direct offering.Phio revealed agreements to sell 1.1 million common shares at $3 each, with a concurrent private placement issuing short-term warrants to purchase 2.1 million shares at the same price.&nbsp;The combined transactions are expected to generate approximately $3.2 million in gross proceeds, earmarked for working capital and other corporate purposes.Despite the sharp decline, retail investors remain optimistic, as evidenced by a Stocktwits poll where nearly 50% of over 900 participants believe the stock has "more room to run."&nbsp;Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.Retail sentiment on Stocktwits turned 'extremely bullish' on Tuesday, with many users predicting a post-offering rally fueled by Phio's low float and the potential of its drug pipeline.&nbsp;Some highlighted the company's ongoing trial progress, while others saw the price drop as a buying opportunity.<stembedurl>https://stocktwits.com/pragash2094/message/599992949</stembedurl><stembedurl>https://stocktwits.com/HUBC1/message/599986181</stembedurl><stembedurl>https://stocktwits.com/TrendIsMyFriend/message/599998502</stembedurl>Like many early-stage biotech firms, Phio has yet to generate revenue. However, its latest financial report showed narrowed losses of $1.5 million for the quarter ended Sept. 30, compared to $2.8 million a year earlier.&nbsp;The company reported $5.4 million in cash, down from $8.4 million a year earlier but more than $4.7 million at the end of the previous quarter.The stock has lost nearly 50% of its value over the past year but has seen retail interest soar. The number of new followers on Stocktwits jumped by over 9%, while message volume increased more than 1,600-fold.With a short interest of 3.8% and ongoing developments in its PH-762 trial, retail investors remain laser-focused on updates about higher-dose concentrations and further enrollment milestones.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Phio’s stock has lost nearly 50% of its value over the past year but has seen retail interest soar. | Image source: Maria Korneeva on Getty Images

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to become the top gainer across U.S. bourses.&nbsp;This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.&nbsp;Trading volume soared to over 220 times the daily average, drawing significant attention from retail investors.Phio revealed that patients in the second cohort of its ongoing trial exhibited these pathologic responses: Two patients with cutaneous squamous cell carcinoma experienced a complete response (100% tumor clearance); one patient had a partial response (90% tumor clearance); one patient maintained stable disease, with no progression.The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.&nbsp;Importantly, no dose-limiting toxicities or clinically relevant adverse events have been reported, and the intratumoral injections have been well tolerated, the company said.Mary Spellman, Acting chief medical officer of Phio, expressed optimism about the tumor responses, saying, “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”&nbsp;"These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said CEO Robert Bitterman.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PHIO_sentiment_meter_and_message_volume_Jan_13_38cb5ff222.png" alt="PHIO sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>PHIO sentiment meter and message volume Jan 13 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Phio spiked to 'extremely bullish' levels, with users sharing optimistic price targets and success stories.<stembedurl>https://stocktwits.com/M105/message/599814732</stembedurl><stembedurl>https://stocktwits.com/Ian980/message/599806765</stembedurl><a href="https://stocktwits.com/symbol/PHIO">Phio’s stock</a> has gained nearly 15% over the past 12 months, with Monday’s rally marking a sharp shift in momentum.&nbsp;Investors are closely watching for further enrollment updates and results from higher dose concentrations in the ongoing trial.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. | Image source: Getty Images

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

PHIO
Phio Pharmaceuticals Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PHIO News

PHIOPhio Pharmaceuticals Corp